Keymed Biosciences, Inc. (HK:2162)
:2162
2162 Stock Chart & Stats
HK$62.80
HK$0.80(2.86%)
At close: 4:00 PM EST
HK$62.80
HK$0.80(2.86%)
Day’s Range― - ―
52-Week RangeHK$34.15 - HK$80.00
Previous CloseN/A
Volume918.50K
Average Volume (3M)1.75M
Market Cap
HK$20.03B
Enterprise ValueHK$18.71B
Total Cash (Recent Filing)HK$2.80B
Total Debt (Recent Filing)HK$872.30M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Sep 01, 2026EPS Estimate
6.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding298,735,570
10 Day Avg. Volume1,976,819
30 Day Avg. Volume1,752,076
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)3.07
Price to Sales (P/S)17.76
P/FCF Ratio-7.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$84.57Price Target Upside34.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.88
Revenue Forecast (FY)HK$1.66B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained multi-year revenue expansion shows durable demand for Keymed's therapies and progress commercializing assets. Strong top-line growth improves funding optionality, strengthens partnership negotiating leverage, and reduces execution risk as the company scales clinical and commercial activities.
Low LeverageA conservative capital structure with low leverage provides financial flexibility to fund R&D and absorb losses without immediate refinancing pressure. This supports a longer runway for clinical programs, lowers solvency risk, and enhances ability to secure non-dilutive or partnership funding on favorable terms.
High Gross MarginStrong gross margins indicate attractive unit economics for Keymed's biologics and proprietary therapies. If operating expenses are controlled or revenues scale, margins can flow through to operating profits faster than low-margin peers, supporting sustainable profitability once commercial scale is achieved.
Bears Say
Negative Free Cash FlowPersistent negative free cash flow and lack of operating cash generation create a structural funding gap. The company will likely need external financing or milestone-based partner payouts to sustain operations, raising dilution risk and constraining strategic flexibility for trials and commercialization investments.
Ongoing Net LossesConsistent net losses and negative EBIT reflect high operating expenses relative to revenue. Until the company meaningfully reduces OPEX or achieves scale, profitability metrics and return on equity will remain weak, limiting internal cash generation and straining long-term financial sustainability.
Dependence On Partnerships/FundingHeavy reliance on strategic partnerships, milestone payments and grants makes revenue timing and size uncertain. Partner decisions or funding shifts can materially affect development and commercialization plans, increasing execution risk and the potential for revenue volatility or project delays.
Keymed Biosciences, Inc. News
2162 FAQ
What was Keymed Biosciences, Inc.’s price range in the past 12 months?
Keymed Biosciences, Inc. lowest stock price was HK$34.15 and its highest was HK$80.00 in the past 12 months.
What is Keymed Biosciences, Inc.’s market cap?
Keymed Biosciences, Inc.’s market cap is HK$20.03B.
When is Keymed Biosciences, Inc.’s upcoming earnings report date?
Keymed Biosciences, Inc.’s upcoming earnings report date is Sep 01, 2026 which is in 148 days.
How were Keymed Biosciences, Inc.’s earnings last quarter?
Keymed Biosciences, Inc. released its earnings results on Mar 26, 2026. The company reported -HK$1.82 earnings per share for the quarter, missing the consensus estimate of -HK$1.485 by -HK$0.335.
Is Keymed Biosciences, Inc. overvalued?
According to Wall Street analysts Keymed Biosciences, Inc.’s price is currently Undervalued.
Does Keymed Biosciences, Inc. pay dividends?
Keymed Biosciences, Inc. does not currently pay dividends.
What is Keymed Biosciences, Inc.’s EPS estimate?
Keymed Biosciences, Inc.’s EPS estimate is 6.51.
How many shares outstanding does Keymed Biosciences, Inc. have?
Keymed Biosciences, Inc. has 298,735,570 shares outstanding.
What happened to Keymed Biosciences, Inc.’s price movement after its last earnings report?
Keymed Biosciences, Inc. reported an EPS of -HK$1.82 in its last earnings report, missing expectations of -HK$1.485. Following the earnings report the stock price went up 0.174%.
Which hedge fund is a major shareholder of Keymed Biosciences, Inc.?
Currently, no hedge funds are holding shares in HK:2162
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keymed Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$84.57 (34.66% Upside)
HK$84.57 (34.66% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.01%
12-Months-Change
Fundamentals
Return on Equity
-17.26%
Trailing 12-Months
Asset Growth
17.19%
Trailing 12-Months
Company Description
Keymed Biosciences, Inc.
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
2162 Stock 12 Month Forecast
Average Price Target
HK$84.57
▲(34.66% Upside)
Technical Analysis
Ascletis Pharma, Inc.
―
Simcere Pharmaceutical Group Limited
―
Lepu Biopharma Co. Ltd. Class H
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Options Prices
Currently, No data available
---